Eli Lilly: positive results for galcanezumab.
(CercleFinance.com) - Eli Lilly has announced positive results for its drug galcanezumab in a Phase III trial: over a 12-month treatment period, the drug was associated with a statistically significant reduction in the number of days patients suffered from migraine.
"These long-term results are significant for the millions of Americans with migraine. They reinforce the efficacy and safety profile of galcanezumab while supporting its potential use as a self-administered, monthly injection," said Christi Shaw, president of Lilly Bio-Medicines.
The Indianapolis-based pharmaceutical company plans to submit a biological license application to the American FDA in the second half of 2017, before other regulatory authorities worldwide.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
"These long-term results are significant for the millions of Americans with migraine. They reinforce the efficacy and safety profile of galcanezumab while supporting its potential use as a self-administered, monthly injection," said Christi Shaw, president of Lilly Bio-Medicines.
The Indianapolis-based pharmaceutical company plans to submit a biological license application to the American FDA in the second half of 2017, before other regulatory authorities worldwide.
Copyright (c) 2017 CercleFinance.com. All rights reserved.